XGN · Exagen Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-08-04 12:30 UTC | Q2 2026 Earnings Call | Earnings call |
Recent news
| Date | Headline |
|---|---|
| 2026-07-21 |
Exagen to Announce Second Quarter Financial Results on August 4, 2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026. |
| 2026-06-01 |
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical |
| 2026-05-11 |
Exagen Inc. Reports First Quarter 2026 Results
Delivers record total revenue and AVISE(R) CTD average selling price CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates. |
| 2026-04-27 |
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive |
| 2026-03-10 |
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
Record full-year total revenue and AVISE ® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported |
| 2026-03-03 |
Exagen Inc. to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank Capital Markets Healthcare Forum - Virtual Date: March 17, 2026 Participation: |
| 2026-02-24 |
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. |
| 2026-01-11 |
Exagen Inc. Announces Select Preliminary 2025 Financial Results
CARLSBAD, Calif. , Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025 , in line with prior financial guidance. |
| 2025-11-11 |
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
CARLSBAD, Calif. , Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: 16 th Annual Craig-Hallum Alpha Select Conference Date: November 18, 2025 |
| 2025-11-04 |
Exagen Inc. Reports Strong Q3 2025 Results
CARLSBAD, Calif. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025 , and recent corporate updates. Three Months Ended September 30 , Nine Months Ended |
| 2025-10-23 |
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
CARLSBAD, Calif. , Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025 , at |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-05-11 | Q1 2026 Earnings Call | Earnings call |
| 2026-03-23 | Roth Capital Conference | Conference |
| 2026-03-17 | KeyBank Capital Markets Healthcare Forum | Event |
| 2026-03-10 | Q4 2025 Earnings Call | Earnings call |
| 2025-11-04 | Q3 2025 Earnings Call | Earnings call |
| 2025-07-29 | Q2 2025 Earnings Call | Earnings call |
| 2025-05-05 | Q1 2025 Earnings Call | Earnings call |
| 2025-03-11 | Q4 2024 Earnings Call | Earnings call |
| 2025-03-05 | TD Cowen 45th Annual Health Care Conference | Conference |
| 2024-11-21 | CG MedTech, Diagnostics and Digital Health & Services Forum | Event |
Source: https://investors.exagen.com/